BiotechTube
Home/ONL Therapeutics/David C., M.D.
DC

David C., M.D.

Chief Medical Officer

ONL Therapeutics

Therapeutic Areas

OphthalmologyRetinal Diseases

ONL Therapeutics Pipeline

DrugIndicationPhase
ONL1204Acute Primary Angle-Closure Glaucoma (APACG)Phase 2
ONL1204 (Preclinical)Retinal DetachmentPreclinical
Fas Inhibition PlatformGeographic Atrophy (AMD)Preclinical

Leadership Team at ONL Therapeutics

JR
John R. B.
President & CEO
View full ONL Therapeutics profile